These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 9882925)

  • 41. A single high dose of recombinant factor VIIa combining adjuvant therapy for controlling bleeding episodes in haemophiliacs with inhibitors.
    Chuansumrit A; Sri-Udomporn N; Srimuninnimit V; Juntarukha R
    Haemophilia; 2001 Sep; 7(5):532-4. PubMed ID: 11554948
    [No Abstract]   [Full Text] [Related]  

  • 42. Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors.
    Matino D; Makris M; Dwan K; D'Amico R; Iorio A
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD004449. PubMed ID: 26677005
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and effectiveness of room temperature stable recombinant factor VIIa in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study.
    Kavakli K; Demartis F; Karimi M; Eshghi P; Neme D; Chambost H; Sommer L; Zak M; Benson G
    Haemophilia; 2017 Jul; 23(4):575-582. PubMed ID: 28440004
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimizing on-demand treatment with NovoSeven room temperature stable.
    Negrier C
    Haemophilia; 2010 May; 16 Suppl 3():35-40. PubMed ID: 20586800
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors.
    Iorio A; Matino D; D'Amico R; Makris M
    Cochrane Database Syst Rev; 2010 Aug; (8):CD004449. PubMed ID: 20687076
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
    Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
    Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.
    Jimenez-Yuste V; Núñez R; Romero JA; Montoro B; Espinós B
    Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX.
    Ekert H; Brewin T; Boey W; Davey P; Tilden D
    Haemophilia; 2001 May; 7(3):279-85. PubMed ID: 11380632
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry.
    Salaj P; Kubes R; Cetkovsky P; Capova I; Penka M; Ovesná P; Mesterton J; Lindgren P
    Thromb Res; 2014 Feb; 133(2):162-7. PubMed ID: 24321420
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience.
    Nicolaisen EM
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S119-23. PubMed ID: 9819042
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008).
    Young G; Cooper DL; Gut RZ;
    Haemophilia; 2012 Nov; 18(6):990-6. PubMed ID: 22631073
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa.
    Negrier C; Hay CR
    Semin Thromb Hemost; 2000; 26(4):407-12. PubMed ID: 11092216
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mechanism of action of recombinant activated factor VII: an update.
    Hedner U
    Semin Hematol; 2006 Jan; 43(1 Suppl 1):S105-7. PubMed ID: 16427375
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical experience with recombinant factor VIIa.
    Lusher J; Ingerslev J; Roberts H; Hedner U
    Blood Coagul Fibrinolysis; 1998 Mar; 9(2):119-28. PubMed ID: 9622209
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Treatment and prevention of haemorrhage with recombinant activated factor VII, not only in hemophilia].
    Levi M; Friederich PW; van der Meer J
    Ned Tijdschr Geneeskd; 2002 Dec; 146(52):2534-7. PubMed ID: 12532665
    [TBL] [Abstract][Full Text] [Related]  

  • 57. First 20 years with recombinant FVIIa (NovoSeven).
    Hedner U; Lee CA
    Haemophilia; 2011 Jan; 17(1):e172-82. PubMed ID: 20609014
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding.
    Wang M; Lawrence JB; Quon DV; Ducore J; Simpson ML; Boggio LN; Mitchell IS; Yuan G; Alexander WA; Schved JF
    Haemophilia; 2017 Nov; 23(6):832-843. PubMed ID: 28776894
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors.
    Seremetis S
    Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S29-30. PubMed ID: 14567532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.